HMPL-A83
Hematological Malignancies
Phase 1Active
Key Facts
About HUTCHMED
HUTCHMED is a leading, innovation-driven biopharma focused on oncology and immunology, with a strategy of 'in China, for the world.' The company has successfully brought novel drugs like fruquintinib (ELUNATE®) to market in China and achieved its first global approval with Takeda. Its business model integrates discovery, development, manufacturing, and commercialization, supported by a deep pipeline of both internally discovered and in-licensed assets. HUTCHMED aims to become a global biopharmaceutical leader by advancing its pipeline through strategic global partnerships.
View full company profileTherapeutic Areas
Other Hematological Malignancies Drugs
| Drug | Company | Phase |
|---|---|---|
| Amdizalisib (HMPL-689) | HUTCHMED | Phase 3 |
| DFTX-301 | Definium Therapeutics | Preclinical |
| Preclinical Pipeline | Autolus Therapeutics | Pre-clinical |
| Gamma Delta T Cell Platform | Adicet Bio | Preclinical |